Prakash S. Masand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Prakash S. Masand has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Un Pae
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
16 shared publications - Ashwin A. Patkar
Avance Psychiatry at Centers of Excellence, Raleigh, NC, USA
15 shared publications - Changsu Han
Department of Psychiatry, Korea University College of Medicine, Seoul, Korea
14 shared publications - Soo-Jung Lee
Department of Psychiatry, the Catholic University of Korea College of Medicine, Seoul, Korea
9 shared publications - Won-Myong Bahk
The Catholic University of Korea
7 shared publications - Hayeon Kim
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
- 3 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (3) , 627-640
A Claims Data–Based Comparison of Treatment Continuation between Aripiprazole Once-monthly and Paliperidone Palmitate in Routine Practice
- 3 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (3) , 627-640
Open AccessA Claims Data–Based Comparison of Treatment Continuation between Aripiprazole Once-monthly and Paliperidone Palmitate in Routine Practice
- Open Access
- 1 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 701-713
Two-injection Start Strategy of Aripiprazole Once-monthly Injection: Current Evidence and Clinical Implications
- 1 July 2026
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (4) , 701-713
Open AccessTwo-injection Start Strategy of Aripiprazole Once-monthly Injection: Current Evidence and Clinical Implications
- Open Access
- 30 December 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (1) , 15-29
Brexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease: Clinical Perspectives
Hayeon Kim, Kyung Ho Lee, Changsu Han, Ashwin A. Patkar, Prakash S. Masand, Won-Myong Bahk, Chi-Un Pae. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.24.1252
- 30 December 2025
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 24 (1) , 15-29
Open AccessBrexpiprazole for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease: Clinical Perspectives
Hayeon Kim, Kyung Ho Lee, Changsu Han, Ashwin A. Patkar, Prakash S. Masand, Won-Myong Bahk, Chi-Un Pae. Clin Psychopharmacol Neurosci -0001;0:. https://doi.org/10.9758/cpn.24.1252
- Open Access
- 30 November 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 2043-2056
Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder
Timely initiation of appropriate major depressive disorder (MDD) therapy is crucial. Medicaid-insured patients with MDD have higher healthcare resource utilization (HRU) and costs than commercially insured patients, making this group essential to study. Claims in the MerativeTM MarketScan® Medicaid Database (2016 to 2022) were used to determine all‑cause and mental health (MH)‑related HRU and healthcare costs of US adults with MDD and ≥ 1 pharmacy claim for cariprazine adjunctive to antidepressant treatment. Outcomes were evaluated in patients initiating cariprazine as their first adjunctive therapy and those initiating cariprazine as a subsequent adjunctive therapy (e.g. after another atypical antipsychotic [AA], non-AA, antidepressant treatment combination). HRU and costs were compared with rate ratios (RRs) and mean cost differences between weighted cariprazine adjunctive therapy cohorts. Among 970 Medicaid beneficiaries meeting inclusion criteria, 392 initiated cariprazine as their first adjunctive therapy and 578 initiated it as a subsequent adjunctive therapy. Patients initiating cariprazine first had significantly lower rates of all‑cause emergency department visits (RR [95% CI] = 0.78 [0.66, 0.94], p < .001) and outpatient (OP) visits (0.80 [0.67, 0.92], p = .012) per patient‑year than those initiating cariprazine subsequently. This translated to lower annual all‑cause medical costs (-$2,101 [-$5,096, -$7], p = .048), driven by lower OP costs (-$2,385, [-$5,251, -$492], p = .016) per patient per year. MH‑related HRU and costs were also significantly lower. Findings from this real‑world study of Medicaid beneficiaries indicate that earlier cariprazine use is associated with potential reduction in the substantial humanistic and economic burden of MDD.
- 30 November 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 2043-2056
Open AccessEconomic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder
Timely initiation of appropriate major depressive disorder (MDD) therapy is crucial. Medicaid-insured patients with MDD have higher healthcare resource utilization (HRU) and costs than commercially insured patients, making this group essential to study. Claims in the MerativeTM MarketScan® Medicaid Database (2016 to 2022) were used to determine all‑cause and mental health (MH)‑related HRU and healthcare costs of US adults with MDD and ≥ 1 pharmacy claim for cariprazine adjunctive to antidepressant treatment. Outcomes were evaluated in patients initiating cariprazine as their first adjunctive therapy and those initiating cariprazine as a subsequent adjunctive therapy (e.g. after another atypical antipsychotic [AA], non-AA, antidepressant treatment combination). HRU and costs were compared with rate ratios (RRs) and mean cost differences between weighted cariprazine adjunctive therapy cohorts. Among 970 Medicaid beneficiaries meeting inclusion criteria, 392 initiated cariprazine as their first adjunctive therapy and 578 initiated it as a subsequent adjunctive therapy. Patients initiating cariprazine first had significantly lower rates of all‑cause emergency department visits (RR [95% CI] = 0.78 [0.66, 0.94], p < .001) and outpatient (OP) visits (0.80 [0.67, 0.92], p = .012) per patient‑year than those initiating cariprazine subsequently. This translated to lower annual all‑cause medical costs (-$2,101 [-$5,096, -$7], p = .048), driven by lower OP costs (-$2,385, [-$5,251, -$492], p = .016) per patient per year. MH‑related HRU and costs were also significantly lower. Findings from this real‑world study of Medicaid beneficiaries indicate that earlier cariprazine use is associated with potential reduction in the substantial humanistic and economic burden of MDD.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 235-244
Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder
Inadequate response to antidepressant therapy (ADT) is common in major depressive disorder (MDD); atypical antipsychotic (AA) adjunctive therapy may be effective for these patients. This study aimed to compare healthcare resource utilization (HRU) and costs between patients initiating the AA cariprazine as their first adjunctive therapy vs those initiating cariprazine subsequently. The MerativeTM MarketScan® Commercial Database (January 1, 2015, to June 30, 2021) was used to identify US adults with MDD and ≥1 pharmacy claim for cariprazine adjunctive to ADT in 2018 or after. Rates of mental health (MH)‑related and all‑cause HRU per patient-year (PPY) and mean healthcare costs per-patient-per-year (PPPY) were assessed after patients first initiated adjunctive therapy. HRU and costs were compared between cohorts using rate ratios (RRs) and mean cost differences, respectively, estimated from multivariable regression models. Of 838 patients receiving cariprazine, 44.7% initiated cariprazine as their first adjunctive therapy to ADT, and 55.3% initiated it subsequently. Those initiating cariprazine first had significantly lower rates of MH‑related hospitalizations (RR [95% confidence interval] = 0.55 [0.30, 0.90], P = 0.020) and outpatient (OP) visits (0.67 [0.57, 0.82], P < 0.001) PPY than those initiating cariprazine subsequently. Moreover, patients initiating cariprazine as their first adjunctive therapy had lower annual total MH‑related healthcare costs (mean cost difference [95% confidence interval] -$2,182 [-$4,206, -$69], P = 0.040), driven primarily by lower OP visit costs (-$1,511 [-$2,330, -$615], P < 0.001). Similar trends were observed for all-cause HRU and costs. This was a retrospective analysis of secondary data with limited follow-up. Claims were a proxy for cariprazine use. Results from this real‑world study of commercially insured US adults suggest that initiating cariprazine as the first adjunctive therapy rather than a subsequent therapy could help mitigate the considerable economic burden of MDD for appropriate patients.
- 1 February 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 235-244
Open AccessHealthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder
Inadequate response to antidepressant therapy (ADT) is common in major depressive disorder (MDD); atypical antipsychotic (AA) adjunctive therapy may be effective for these patients. This study aimed to compare healthcare resource utilization (HRU) and costs between patients initiating the AA cariprazine as their first adjunctive therapy vs those initiating cariprazine subsequently. The MerativeTM MarketScan® Commercial Database (January 1, 2015, to June 30, 2021) was used to identify US adults with MDD and ≥1 pharmacy claim for cariprazine adjunctive to ADT in 2018 or after. Rates of mental health (MH)‑related and all‑cause HRU per patient-year (PPY) and mean healthcare costs per-patient-per-year (PPPY) were assessed after patients first initiated adjunctive therapy. HRU and costs were compared between cohorts using rate ratios (RRs) and mean cost differences, respectively, estimated from multivariable regression models. Of 838 patients receiving cariprazine, 44.7% initiated cariprazine as their first adjunctive therapy to ADT, and 55.3% initiated it subsequently. Those initiating cariprazine first had significantly lower rates of MH‑related hospitalizations (RR [95% confidence interval] = 0.55 [0.30, 0.90], P = 0.020) and outpatient (OP) visits (0.67 [0.57, 0.82], P < 0.001) PPY than those initiating cariprazine subsequently. Moreover, patients initiating cariprazine as their first adjunctive therapy had lower annual total MH‑related healthcare costs (mean cost difference [95% confidence interval] -$2,182 [-$4,206, -$69], P = 0.040), driven primarily by lower OP visit costs (-$1,511 [-$2,330, -$615], P < 0.001). Similar trends were observed for all-cause HRU and costs. This was a retrospective analysis of secondary data with limited follow-up. Claims were a proxy for cariprazine use. Results from this real‑world study of commercially insured US adults suggest that initiating cariprazine as the first adjunctive therapy rather than a subsequent therapy could help mitigate the considerable economic burden of MDD for appropriate patients.
- Open Access
- 4 February 2024
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 22 (2) , 370-375
The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Seung-Hoon Lee, Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2024;22:370-5. https://doi.org/10.9758/cpn.23.1106
- 4 February 2024
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 22 (2) , 370-375
Open AccessThe Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
Seung-Hoon Lee, Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2024;22:370-5. https://doi.org/10.9758/cpn.23.1106
- Open Access
- 31 August 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (3) , 594-598
Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2023;21:594-8. https://doi.org/10.9758/cpn.23.1060
- 31 August 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (3) , 594-598
Open AccessAdditional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
Kyung Ho Lee, Tae Sun Han, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae. Clin Psychopharmacol Neurosci 2023;21:594-8. https://doi.org/10.9758/cpn.23.1060
- Open Access
- 28 February 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (1) , 135-146
Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
Cheolmin Shin, Sang Won Jeon, Seung-Hoon Lee, Chi-Un Pae, Narei Hong, Hyun Kook Lim, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An, Changsu Han. Clin Psychopharmacol Neurosci 2023;21:135-46. https://doi.org/10.9758/cpn.2023.21.1.135
- 28 February 2023
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 21 (1) , 135-146
Open AccessEfficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
Cheolmin Shin, Sang Won Jeon, Seung-Hoon Lee, Chi-Un Pae, Narei Hong, Hyun Kook Lim, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An, Changsu Han. Clin Psychopharmacol Neurosci 2023;21:135-46. https://doi.org/10.9758/cpn.2023.21.1.135
- Open Access
- 25 April 2022
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 19 (4) , 268-280
Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine, and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive complaint (CC).Methods A total of 129 patients with MDD who also complained of CC were randomized evenly to either escitalopram, vortioxetine, or desvenlafaxine group and underwent a multi-center, six-week, rater-blinded, and head-to-head comparative trial. Differences in depressive symptoms following treatment were measured using the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Åsberg Depression Rating Scale (MADRS). Subjective cognitive function and the presence of adverse events were assessed.Results The three antidepressant treatment groups did not show significant differences in the improvement of depressive symptoms as measured by HAMD and MADRS. Desvenlafaxine treatment was associated with a superior treatment response rate in depressive symptoms compared to vortioxetine or escitalopram treatment. However, no significant differences were found in the remission rate of depressive symptoms. The three antidepressant treatment groups did not show significant differences in the improvement of CC. Adverse profiles of each treatment group were tolerable, with no significant differences.Conclusion In acute antidepressant treatment for MDD with CC, escitalopram, vortioxetine, and desvenlafaxine presented similar efficacy in relief of depressive symptoms; however, desvenlafaxine was associated with a superior treatment. Further studies are needed to confirm these results by investigating the therapeutic efficacy and safety profile of long-term antidepressant treatment of MDD with CC (Clinical Trial Registry, http://cris.nih.go.kr/cris/en/: KCT0002173).
- 25 April 2022
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 19 (4) , 268-280
Open AccessAcute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine, and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive complaint (CC).Methods A total of 129 patients with MDD who also complained of CC were randomized evenly to either escitalopram, vortioxetine, or desvenlafaxine group and underwent a multi-center, six-week, rater-blinded, and head-to-head comparative trial. Differences in depressive symptoms following treatment were measured using the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Åsberg Depression Rating Scale (MADRS). Subjective cognitive function and the presence of adverse events were assessed.Results The three antidepressant treatment groups did not show significant differences in the improvement of depressive symptoms as measured by HAMD and MADRS. Desvenlafaxine treatment was associated with a superior treatment response rate in depressive symptoms compared to vortioxetine or escitalopram treatment. However, no significant differences were found in the remission rate of depressive symptoms. The three antidepressant treatment groups did not show significant differences in the improvement of CC. Adverse profiles of each treatment group were tolerable, with no significant differences.Conclusion In acute antidepressant treatment for MDD with CC, escitalopram, vortioxetine, and desvenlafaxine presented similar efficacy in relief of depressive symptoms; however, desvenlafaxine was associated with a superior treatment. Further studies are needed to confirm these results by investigating the therapeutic efficacy and safety profile of long-term antidepressant treatment of MDD with CC (Clinical Trial Registry, http://cris.nih.go.kr/cris/en/: KCT0002173).
- Open Access
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 600-609
Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
Jung-Jin Kim, Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand. Clin Psychopharmacol Neurosci 2021;19:600-9. https://doi.org/10.9758/cpn.2021.19.4.600
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 600-609
Open AccessExploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
Jung-Jin Kim, Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand. Clin Psychopharmacol Neurosci 2021;19:600-9. https://doi.org/10.9758/cpn.2021.19.4.600